{"id":"brivaracetam-ucb-34714","safety":{"commonSideEffects":[{"rate":"15–30%","effect":"Somnolence"},{"rate":"10–20%","effect":"Fatigue"},{"rate":"10–15%","effect":"Dizziness"},{"rate":"5–10%","effect":"Headache"},{"rate":"5–10%","effect":"Irritability/mood changes"},{"rate":"5–10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL607400","moleculeType":"Small molecule","molecularWeight":"212.29"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brivaracetam is a high-affinity ligand for SV2A, a synaptic vesicle glycoprotein involved in neurotransmitter release and neuronal excitability. By binding to SV2A with greater selectivity and potency than levetiracetam, it modulates calcium-dependent exocytosis and reduces the release of excitatory neurotransmitters, thereby suppressing seizure activity. This mechanism makes it effective as an antiepileptic agent with a potentially improved tolerability profile.","oneSentence":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:47:19.321Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of partial-onset seizures in epilepsy"},{"name":"Generalized tonic-clonic seizures (pipeline indication)"}]},"trialDetails":[{"nctId":"NCT05639946","phase":"PHASE3","title":"Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-01-01","conditions":"Spinal Cord Injuries, Neuropathic Pain","enrollment":44},{"nctId":"NCT06315322","phase":"PHASE3","title":"A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2024-07-10","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":120},{"nctId":"NCT04666610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-07-29","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":153},{"nctId":"NCT05899764","phase":"PHASE1, PHASE2","title":"Epileptic Hippocampus in Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2026-01-01","conditions":"Alzheimer Disease, Mild Cognitive Impairment","enrollment":25},{"nctId":"NCT05109234","phase":"PHASE3","title":"A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-03-30","conditions":"Childhood Absence Epilepsy, Juvenile Absence Epilepsy","enrollment":84},{"nctId":"NCT01364597","phase":"PHASE3","title":"Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-08-01","conditions":"Epilepsy","enrollment":257},{"nctId":"NCT03083665","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-22","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":449},{"nctId":"NCT04379011","phase":"PHASE1, PHASE2","title":"Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2021-02-01","conditions":"Spinal Cord Injuries","enrollment":24},{"nctId":"NCT07163572","phase":"NA","title":"Comparison of Intravenous Brivaracetam Versus Levetiracetam in the Management of Status Epilepticus","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-16","conditions":"Status Epilepticus","enrollment":152},{"nctId":"NCT07163585","phase":"NA","title":"Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2024-08-01","conditions":"Epilepsy","enrollment":102},{"nctId":"NCT03250377","phase":"PHASE3","title":"A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2017-08-05","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":207},{"nctId":"NCT04836559","phase":"PHASE2","title":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-18","conditions":"Focal Onset Seizures","enrollment":110},{"nctId":"NCT04715646","phase":"PHASE3","title":"A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures","status":"RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2021-03-11","conditions":"Epilepsy","enrollment":70},{"nctId":"NCT03532516","phase":"","title":"Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy","status":"AVAILABLE","sponsor":"UCB Biopharma SRL","startDate":"","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT06312566","phase":"PHASE1","title":"A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2024-03-25","conditions":"Healthy Study Participants","enrollment":64},{"nctId":"NCT06762743","phase":"PHASE1","title":"Bioequivalence Study of Two Brivaracetam Oral Solutions in Healthy Adults Under Fasting and High-Fat Meal Conditions","status":"ENROLLING_BY_INVITATION","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2024-10-21","conditions":"Epilepsy (treatment Refractory)","enrollment":60},{"nctId":"NCT05029960","phase":"EARLY_PHASE1","title":"Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2022-05-17","conditions":"Brain Tumor","enrollment":30},{"nctId":"NCT05543122","phase":"","title":"Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2022-03-09","conditions":"Breast Feeding","enrollment":39},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT05315947","phase":"PHASE1","title":"A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2022-04-04","conditions":"Healthy Study Participants","enrollment":24},{"nctId":"NCT03517423","phase":"","title":"Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study","status":"COMPLETED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2018-10-04","conditions":"Epilepsy","enrollment":51},{"nctId":"NCT00368251","phase":"PHASE3","title":"Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-11","conditions":"Unverricht-Lundborg Disease","enrollment":56},{"nctId":"NCT04882540","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-05-19","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05278221","phase":"NA","title":"TMS Combined With EEG/EMG as a Biomarker Predicting Antiepileptic Drug Response","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-08-01","conditions":"Focal Epilepsy","enrollment":42},{"nctId":"NCT05622370","phase":"PHASE1","title":"An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.","status":"UNKNOWN","sponsor":"Overseas Pharmaceuticals, Ltd.","startDate":"2022-09-13","conditions":"Partial Seizure","enrollment":12},{"nctId":"NCT01261325","phase":"PHASE3","title":"Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-12","conditions":"Epilepsy","enrollment":768},{"nctId":"NCT00464269","phase":"PHASE3","title":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Epilepsy","enrollment":400},{"nctId":"NCT00490035","phase":"PHASE3","title":"Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2007-09","conditions":"Epilepsy","enrollment":399},{"nctId":"NCT03405714","phase":"PHASE2","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2018-06-01","conditions":"Epilepsy","enrollment":50},{"nctId":"NCT05180916","phase":"NA","title":"Priming the Epileptic Brain: tVNS to Improve Efficacy of add-on AED in Patients With Focal Epilepsy","status":"UNKNOWN","sponsor":"Eindhoven University of Technology","startDate":"2021-08-01","conditions":"Focal Epilepsy","enrollment":66},{"nctId":"NCT00175916","phase":"PHASE3","title":"Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-09","conditions":"Epilepsy","enrollment":853},{"nctId":"NCT01339559","phase":"PHASE3","title":"Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2011-05-11","conditions":"Epilepsy","enrollment":767},{"nctId":"NCT00150800","phase":"PHASE3","title":"This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment","status":"COMPLETED","sponsor":"UCB PHARMA Inc. (US)","startDate":"2006-01","conditions":"Epilepsy","enrollment":668},{"nctId":"NCT02687711","phase":"","title":"Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2016-02-01","conditions":"Epilepsy With POS With or Without Secondary Generalization","enrollment":544},{"nctId":"NCT03685630","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2019-01-04","conditions":"Partial Seizures With or Without Secondary Generalization, Epilepsy","enrollment":10},{"nctId":"NCT03021018","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2017-02-06","conditions":"Epilepsy","enrollment":46},{"nctId":"NCT03695094","phase":"PHASE1","title":"A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2018-09-18","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT03580707","phase":"PHASE2, PHASE3","title":"Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint","status":"COMPLETED","sponsor":"Rosenfeld, William E., M.D.","startDate":"2018-06-01","conditions":"Photosensitive Epilepsy","enrollment":16},{"nctId":"NCT00160667","phase":"PHASE2","title":"A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-10-11","conditions":"Neuralgia, Postherpetic","enrollment":152},{"nctId":"NCT01710670","phase":"PHASE1","title":"A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":18},{"nctId":"NCT00175825","phase":"PHASE2","title":"A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-11-07","conditions":"Epilepsy","enrollment":210},{"nctId":"NCT00699283","phase":"PHASE3","title":"A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2008-08","conditions":"Epilepsy","enrollment":62},{"nctId":"NCT01405508","phase":"PHASE3","title":"Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-08","conditions":"Epilepsy","enrollment":105},{"nctId":"NCT00761774","phase":"PHASE3","title":"An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-11","conditions":"Epilepsy","enrollment":108},{"nctId":"NCT00698581","phase":"PHASE3","title":"A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2008-08","conditions":"Epilepsy","enrollment":88},{"nctId":"NCT01653262","phase":"PHASE3","title":"Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-07","conditions":"Epilepsy","enrollment":29},{"nctId":"NCT02088957","phase":"PHASE2","title":"Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures","status":"TERMINATED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2014-03","conditions":"Nonconvulsive Electrographic Seizures","enrollment":1},{"nctId":"NCT00422422","phase":"PHASE2","title":"Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-07","conditions":"Epilepsy","enrollment":100},{"nctId":"NCT01728077","phase":"PHASE3","title":"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-10","conditions":"Epilepsy","enrollment":26},{"nctId":"NCT00504881","phase":"PHASE3","title":"Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2007-10","conditions":"Epilepsy","enrollment":480},{"nctId":"NCT02602860","phase":"PHASE1","title":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2015-11","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT00357669","phase":"PHASE3","title":"Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2006-11","conditions":"Unverricht-Lundborg Disease","enrollment":50},{"nctId":"NCT00175929","phase":"PHASE2","title":"A Study of Brivaracetam in Subjects With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-05","conditions":"Epilepsy, Focal","enrollment":157},{"nctId":"NCT01796899","phase":"PHASE1","title":"Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-01","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT00736931","phase":"PHASE1","title":"Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2008-07","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT00401648","phase":"PHASE2","title":"Effect of Brivaracetam in Photosensitive Epileptic Subjects","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-09","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT00426673","phase":"PHASE1","title":"An Open-Label Interaction Study to Look at the Effects of Brivaracetam on Phenytoin When Taken Together in 15 Adult Patients With Epilepsy.","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-04","conditions":"Epilepsy","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Brivaracetam (ucb 34714)","genericName":"Brivaracetam (ucb 34714)","companyName":"UCB Pharma","companyId":"ucb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures. Used for Adjunctive treatment of partial-onset seizures in epilepsy, Generalized tonic-clonic seizures (pipeline indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}